Michael Marro, DO
Family Medicine · Concord, VTNPI 1639592983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$425
- GSK$366
- Johnson & Johnson$271
- AstraZeneca$258
- Astellas Pharma US Inc$169
- Lilly USA, LLC$140
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,87597%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $425 |
| GSK | 28 | $366 |
| Johnson & Johnson(2 entities) | 17 | $271 |
| AstraZeneca | 17 | $258 |
| Astellas Pharma US Inc | 6 | $169 |
| Lilly USA, LLC | 9 | $140 |
| Pfizer | 7 | $117 |
| Novo Nordisk | 7 | $113 |
| Medtronic | 2 | $99 |
| Exact Sciences | 4 | $98 |
| Teva Pharmaceuticals USA, Inc. | 7 | $93 |
| Daiichi Sankyo Inc. | 6 | $93 |
| Collegium Pharmaceutical, Inc. | 5 | $82 |
| Boehringer Ingelheim | 5 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $45 |
| Amgen | 3 | $44 |
| Irhythm Technologies, Inc. | 2 | $36 |
| Merck | 2 | $33 |
| Indivior Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 2 | $30 |
| Braeburn Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Corium, LLC | 2 | $28 |
| Abbott | 1 | $24 |
| Dynavax Technologies Corporation | 2 | $22 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Neurelis, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,974 in reported general payments places this provider in the 95th percentile of 106 family medicine providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $45,526 |
| FarxigaDapagliflozin Propanediol | 31 | $32,537 |
| EliquisApixaban | 17 | $25,123 |
| BelbucaBuprenorphine Hcl | 38 | $23,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $19,629 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $19,000 |
| JardianceEmpagliflozin | 14 | $16,513 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $14,294 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 58 | $13,532 |
| TrulicityDulaglutide | 12 | $13,520 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,209 |
| BelsomraSuvorexant | 18 | $6,922 |
| Varenicline Tartrate | 14 | $5,367 |
| Gabapentin | 217 | $5,129 |
| Demeclocycline Hcl | 11 | $4,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $366 | $47,83966 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $258 | $46,83143 claims |
| Novo NordiskOzempic | $113 | $45,52646 claims |
| PfizerEliquis | $117 | $25,12317 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $82 | $23,86638 claims |
| Boehringer IngelheimJardiance | $69 | $16,51314 claims |
| Lilly USA, LLCTrulicity, Humalog | $140 | $16,07024 claims |
| MerckBelsomra | $33 | $6,92218 claims |
| AbbVieSynthroid | $425 | $1,97717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 family medicine providers in Vermont.
Other family medicine in Concord
- John McPartlandMiddlebury$87K
- George FjeldBrandon$2K
- Jonathan StrenioBurlington$1K
- Dylan EstesVergennes$929
- Magda RamirezStowe$379
- Alice KaufmanBrattleboro$288
- Katherine LoganEssex Junction$229
- J Gregory KingBennington$200
- Nicholas WildManchester Center$183
- Karen LawesSouth Hero$183
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.